Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jonasch

Showing results (31-40 of 271) with videos related to

Pageof 28
Sort By:
Future Oncology (London, England)|March 30, 2016
Key considerations in the treatment of von Hippel-Lindau diseasePatrick G Pilié, Eric Jonasch, Ian E McCutcheon
Expert Review of Anticancer Therapy|November 30, 2010
Long-term management of patients with metastatic renal cell carcinoma on targeted agentsEric Jonasch, Lance C Pagliaro, Nizar M Tannir
Biochimica Et Biophysica Acta|March 9, 2013
DDX3 regulates DNA damage-induced apoptosis and p53 stabilizationMianen Sun, Tong Zhou, Eric Jonasch, et al.
Molecular & Cellular Oncology|June 17, 2016
Dysregulation of HIF2α and autophagy in renal cell carcinomaXian-De Liu, Haifeng Zhu, Adela DePavia, et al.
Targeted Oncology|March 1, 2012
Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case reportBetty Y S Kim, Eric Jonasch, Ian E McCutcheon
Expert Review of Anticancer Therapy|June 29, 2011
Systemic therapy for sarcomatoid renal cell carcinomaLance C Pagliaro, Nizar Tannir, Kanishka Sircar, et al.
Cancers|February 15, 2022
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?Eric Jonasch, Michael B Atkins, Simon Chowdhury, et al.
Cancer Genetics|July 19, 2011
Clinical genomics of renal epithelial tumorsJill M Hagenkord, Zoran Gatalica, Eric Jonasch, et al.
Current Clinical Pharmacology|August 11, 2011
Emerging targeted therapies in metastatic renal cell carcinomaMarc R Matrana, Bradley Atkinson, Eric Jonasch, et al.
Cancer|April 13, 2011
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinomaJonathan Verma, Eric Jonasch, Pamela Allen, et al.
Pageof 28

Showing results (31-40 of 271) with videos related to

Sort By:
Pageof 28
Future Oncology (London, England)|March 30, 2016
Key considerations in the treatment of von Hippel-Lindau diseasePatrick G Pilié, Eric Jonasch, Ian E McCutcheon
Expert Review of Anticancer Therapy|November 30, 2010
Long-term management of patients with metastatic renal cell carcinoma on targeted agentsEric Jonasch, Lance C Pagliaro, Nizar M Tannir
Biochimica Et Biophysica Acta|March 9, 2013
DDX3 regulates DNA damage-induced apoptosis and p53 stabilizationMianen Sun, Tong Zhou, Eric Jonasch, et al.
Molecular & Cellular Oncology|June 17, 2016
Dysregulation of HIF2α and autophagy in renal cell carcinomaXian-De Liu, Haifeng Zhu, Adela DePavia, et al.
Targeted Oncology|March 1, 2012
Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case reportBetty Y S Kim, Eric Jonasch, Ian E McCutcheon
Expert Review of Anticancer Therapy|June 29, 2011
Systemic therapy for sarcomatoid renal cell carcinomaLance C Pagliaro, Nizar Tannir, Kanishka Sircar, et al.
Cancers|February 15, 2022
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?Eric Jonasch, Michael B Atkins, Simon Chowdhury, et al.
Cancer Genetics|July 19, 2011
Clinical genomics of renal epithelial tumorsJill M Hagenkord, Zoran Gatalica, Eric Jonasch, et al.
Current Clinical Pharmacology|August 11, 2011
Emerging targeted therapies in metastatic renal cell carcinomaMarc R Matrana, Bradley Atkinson, Eric Jonasch, et al.
Cancer|April 13, 2011
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinomaJonathan Verma, Eric Jonasch, Pamela Allen, et al.
Pageof 28